Stephen Brent Carroll

US Patent:

6376217, Apr 23, 2002

Filed:

Jul 6, 2000

Appl. No.:

09/610838

Inventors:

Marc D. Better - Los Angeles CA
Stephen F. Carroll - Walnut Creek CA

Assignee:

Xoma Technology Ltd.

International Classification:

C12P 2102

US Classification:

435 691, 536 236, 536 234, 536 232, 5363919, 530326, 530350

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

6599880, Jul 29, 2003

Filed:

May 25, 2000

Appl. No.:

09/579403

Inventors:

Arnold Horwitz - Los Angeles CA
Stephen F. Carroll - Walnut Creek CA
David Burke - Oakland CA

Assignee:

Xoma Corporation - Berkeley CA

International Classification:

A61K 3800

US Classification:

514 12, 514 2, 530350, 435 691, 4353201, 435325

Abstract:

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.

US Patent:

6649742, Nov 18, 2003

Filed:

Nov 13, 2000

Appl. No.:

09/711485

Inventors:

Marc D. Better - Los Angeles CA
Stephen F. Carroll - Walnut Creek CA
Gary M. Studnicka - Santa Monica CA

Assignee:

XOMA Technology Ltd.

International Classification:

C07K 1600

US Classification:

5303873, 530866

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

7153932, Dec 26, 2006

Filed:

Nov 18, 2003

Appl. No.:

10/717243

Inventors:

Marc D. Better - Los Angeles CA, US
Stephen F. Carroll - Walnut Creek CA, US
Gary M. Studnicka - Santa Monica CA, US

Assignee:

Research Development Foundation - Carson City NV

International Classification:

C07K 16/00
A61K 38/16
A61K 38/10
C12P 21/08

US Classification:

530326, 530350, 5303873, 530866

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

20030166196, Sep 4, 2003

Filed:

Apr 23, 2002

Appl. No.:

10/127890

Inventors:

Marc Better - Los Angeles CA, US
Stephen Carroll - Walnut Creek CA, US

Assignee:

XOMA Technology Ltd.

International Classification:

C07K016/00
C07H021/04
C12P021/06
C12N009/00
C12P021/08
C07K005/00
C07K007/00
C07K017/00
A61K038/00
A61K038/04
C07K001/00
C07K014/00

US Classification:

435/188500, 435/069100, 530/326000, 530/350000, 530/391900, 536/023200, 536/023400, 536/023600

Abstract:

The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transformed with the vectors are also provided. The RIPs and RIP analogs are particularly suited for use as components of cytotoxic therapeutic agents of the invention which include gene fusion products and immunoconjugates. Cytotoxic therapeutic agents or immunotoxins according to the present invention may be used to selectively eliminate any cell type to which the RIP component is targeted by the specific binding capacity of the second component of the agent, and are suited for treatment of diseases where the elimination of a particular cell type is a goal, such as autoimmune disease, cancer and graft-versus-host disease.

US Patent:

20050130889, Jun 16, 2005

Filed:

Jul 29, 2003

Appl. No.:

10/629516

Inventors:

Arnold Horwitz - Los Angeles CA, US
Stephen Carroll - Walnut Creek CA, US
David Burke - Oakdale CA, US

International Classification:

A61K038/16
C07H021/04
C12N015/74
C12N009/48

US Classification:

514012000, 435069300, 435320100, 435212000, 435252300, 536023700

Abstract:

Novel BPI deletion analogs are provided that consist of amino acid residues 10 through 193 of mature human BPI wherein the cysteine residue at BPI amino acid position 132 is replaced by another amino acid. Fusion proteins comprising these analogs are also provided, as are polynucleotides encoding these products, materials and methods for their recombinant production, compositions and medicaments of these products, and therapeutic uses for these products.

US Patent:

61468509, Nov 14, 2000

Filed:

Aug 18, 1998

Appl. No.:

9/136389

Inventors:

Marc D. Better - Los Angeles CA
Stephen F. Carroll - Walnut Creek CA

Assignee:

Xoma Corporation - Berkeley CA

International Classification:

C12P 2102

US Classification:

435 691

Abstract:

The present invention provides purified proteins that contain gelonin amino acid sequences that have enzymatic activity.

US Patent:

60935731, Jul 25, 2000

Filed:

Jun 20, 1997

Appl. No.:

8/879565

Inventors:

Lesa J. Beamer - Santa Monica CA
Stephen F. Carroll - Walnut Creek CA
David Eisenberg - Los Angeles CA

Assignee:

XOMA - Berkeley CA
The Regents of the University of California - Oakland CA

International Classification:

G01N 3348

US Classification:

436 86

Abstract:

The present invention provides a crystallized Bactericidal Permeability-Increasing (BPI) protein; methods for x-ray diffraction analysis to provide x-ray diffraction patterns of sufficiently high resolution for three-dimensional structure determination of the protein, as well as methods for rational drug design, based on using amino acid sequence data and/or x-ray crystallography data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms; and atomic coordinates are provided yielding structural information on the lipid binding and lipid transport protein family that includes BPI, LBP, CETP and PLTP.